Prevalence of Weight Gain and Associated Factors Among People Living with HIV 6- and 12-Months Post Dolutegravir-Based Anti-Retroviral Regimen Initiation in Gulu, Uganda; A Hospital-Based Retrospective Cohort Study.

IF 2.4 Q4 INFECTIOUS DISEASES

HIV AIDS-Research and Palliative Care Pub Date : 2025-11-04 eCollection Date: 2025-01-01 DOI:10.2147/HIV.S548947

Nobert Moris Kasibante, Nelson Tokema, Alfred Douglas Kilama, Michael Mpuuga, Ivaan Pitua, Jerom Okot, Felix Bongomin

{"title":"Prevalence of Weight Gain and Associated Factors Among People Living with HIV 6- and 12-Months Post Dolutegravir-Based Anti-Retroviral Regimen Initiation in Gulu, Uganda; A Hospital-Based Retrospective Cohort Study.","authors":"Nobert Moris Kasibante, Nelson Tokema, Alfred Douglas Kilama, Michael Mpuuga, Ivaan Pitua, Jerom Okot, Felix Bongomin","doi":"10.2147/HIV.S548947","DOIUrl":null,"url":null,"abstract":"Background: Dolutegravir (DTG), an integrase-strand transfer inhibitor approved by WHO in 2019 as part of first-line HIV treatment, has been linked to weight gain; however, data on this and its associated factors remain limited.Objective: This study aimed to determine the prevalence of weight gain and associated factors among people living with HIV (PLHIV) on DTG-based antiretroviral therapy (ART) regimens.Methods: We conducted a retrospective cohort study of PLHIV at St. Mary's Hospital Lacor between January 2020 and December 2021. Charts were reviewed for demographic and clinical data at baseline, at 6 months and at 12 months. Weight gain was defined as a ≥5% increase in weight from baseline at 6 months. Bivariate analysis followed by stepwise multivariable logistic regression was used to identify independent predictors of weight gain. Data were analyzed using STATA 17.Results: A total of 432 participants were included, 83.8% of whom were female. The median age was 44 years (IQR: 37.0-49.5). Most (97.0%) programmatically switched to DTG-based regimens. The prevalence of weight gain (defined as ≥5% increase from baseline) at 6 months was 7.4% (n=32/432) and 16.5% (n=31/187) at 12 months. Mean weight at baseline and 6 months was comparable (61.0 kg vs 60.0 kg, p=0.108), but a statistically significant increase in weight (p<0.001) and BMI (p<0.001) was observed from baseline to 12 months. On bivariate analysis, lower baseline WHO stage (p=0.048) and viral load <1000 copies/mL (p=0.009) were associated with weight gain; however, no factor remained significantly associated in multivariable analysis.Conclusion: Weight gain occured in approximately 1 in 14 participants at 6 months and 1 in 6 participants at 12 months post-DTG initiation. WHO stage I and lower viral load were associated with weight gain on bivariate analysis, though not independently on multivariable analysis. Routine weight and cardiovascular risk monitoring is recommended. A prospective study is warranted.","PeriodicalId":46555,"journal":{"name":"HIV AIDS-Research and Palliative Care","volume":"17 ","pages":"361-372"},"PeriodicalIF":2.4000,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12595951/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV AIDS-Research and Palliative Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/HIV.S548947","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Dolutegravir (DTG), an integrase-strand transfer inhibitor approved by WHO in 2019 as part of first-line HIV treatment, has been linked to weight gain; however, data on this and its associated factors remain limited.

Objective: This study aimed to determine the prevalence of weight gain and associated factors among people living with HIV (PLHIV) on DTG-based antiretroviral therapy (ART) regimens.

Methods: We conducted a retrospective cohort study of PLHIV at St. Mary's Hospital Lacor between January 2020 and December 2021. Charts were reviewed for demographic and clinical data at baseline, at 6 months and at 12 months. Weight gain was defined as a ≥5% increase in weight from baseline at 6 months. Bivariate analysis followed by stepwise multivariable logistic regression was used to identify independent predictors of weight gain. Data were analyzed using STATA 17.

Results: A total of 432 participants were included, 83.8% of whom were female. The median age was 44 years (IQR: 37.0-49.5). Most (97.0%) programmatically switched to DTG-based regimens. The prevalence of weight gain (defined as ≥5% increase from baseline) at 6 months was 7.4% (n=32/432) and 16.5% (n=31/187) at 12 months. Mean weight at baseline and 6 months was comparable (61.0 kg vs 60.0 kg, p=0.108), but a statistically significant increase in weight (p<0.001) and BMI (p<0.001) was observed from baseline to 12 months. On bivariate analysis, lower baseline WHO stage (p=0.048) and viral load <1000 copies/mL (p=0.009) were associated with weight gain; however, no factor remained significantly associated in multivariable analysis.

Conclusion: Weight gain occured in approximately 1 in 14 participants at 6 months and 1 in 6 participants at 12 months post-DTG initiation. WHO stage I and lower viral load were associated with weight gain on bivariate analysis, though not independently on multivariable analysis. Routine weight and cardiovascular risk monitoring is recommended. A prospective study is warranted.

Abstract Image

查看原文本刊更多论文

乌干达古卢地区艾滋病毒感染者在开始多路替格雷韦抗逆转录病毒治疗6个月和12个月后体重增加的流行率及相关因素一项基于医院的回顾性队列研究

背景：Dolutegravir （DTG）是一种整合酶链转移抑制剂，于2019年被世卫组织批准作为一线艾滋病毒治疗的一部分，与体重增加有关；然而，关于这一点及其相关因素的数据仍然有限。目的：本研究旨在确定基于dtg的抗逆转录病毒治疗（ART）方案的HIV感染者（PLHIV）体重增加的患病率及其相关因素。方法：我们于2020年1月至2021年12月在Lacor圣玛丽医院进行了一项PLHIV回顾性队列研究。回顾了基线、6个月和12个月时的人口学和临床数据。体重增加定义为6个月时体重较基线增加≥5%。采用双变量分析和逐步多变量逻辑回归来确定体重增加的独立预测因素。使用STATA 17分析数据。结果：共纳入432名受试者，其中女性占83.8%。中位年龄44岁（IQR: 37.0 ~ 49.5）。大多数（97.0%）有计划地切换到基于dtg的方案。6个月时体重增加（定义为比基线增加≥5%）的患病率为7.4% (n=32/432)， 12个月时为16.5% （n=31/187）。基线和6个月的平均体重相当（61.0 kg vs 60.0 kg, p=0.108），但体重有统计学意义上的显著增加(结论：dtg开始后6个月和12个月，14名参与者中约有1名体重增加。在双变量分析中，世卫组织I期和较低的病毒载量与体重增加有关，但在多变量分析中不是独立的。建议进行常规体重和心血管风险监测。有必要进行前瞻性研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

HIV AIDS-Research and Palliative Care INFECTIOUS DISEASES-

CiteScore

3.00

自引率

6.70%

发文量

审稿时长

16 weeks

期刊介绍： About Dove Medical Press Dove Medical Press Ltd is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC. We specialize in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine. Dove Medical Press was founded in 2003 with the objective of combining the highest editorial standards with the ''best of breed'' new publishing technologies. We have offices in Manchester and London in the United Kingdom, representatives in Princeton, New Jersey in the United States, and our editorial offices are in Auckland, New Zealand. Dr Scott Fraser is our Medical Director based in the UK. He has been in full time clinical practice for over 20 years as well as having an active research interest.